Single high-dose treatment with glucosaminyl-muramyl dipeptide is ineffective in treating ankylosing spondylitis

Olga V. Britanova, Dmitriy B. Staroverov, Anna V. Chkalina, Alexei A. Kotlobay, Ekaterina S. Zvezdova, Anna G. Bochkova, Dmitriy M. Chudakov

Результат исследований: Вклад в журналСтатьярецензирование

3 Цитирования (Scopus)

Аннотация

Earlier studies have shown that high doses of TNF-alpha increase apoptosis in human autoimmune T-cell clones. Based on these studies, a treatment approach was proposed to reduce or eliminate autoimmune T cells in patients with type 1 diabetes using drugs that temporarily elevate TNF levels. Here, we report the treatment of ankylosing spondylitis patient with a single high oral dose of Likopid (glucosaminyl-muramyl dipeptide), which aimed at increasing the levels of TNF-alpha in order to induce apoptosis of autoreactive T cells. The flow cytometric analysis of blood samples collected before and after treatment demonstrated massive elimination of CD8 + T cells. However, the treatment did not result in any notable therapeutic effect, and real-time PCR analysis demonstrated that stably expanded T-cell clones that were earlier tracked in this patient were unaffected. This report suggests that the controversial approach to eliminate autoimmune T-cell clones through overstimulation is not effective in treating ankylosing spondylitis.

Язык оригиналаАнглийский
Страницы (с-по)1101-1103
Число страниц3
ЖурналRheumatology International
Том31
Номер выпуска8
DOI
СостояниеОпубликовано - авг. 2011
Опубликовано для внешнего пользованияДа

Fingerprint

Подробные сведения о темах исследования «Single high-dose treatment with glucosaminyl-muramyl dipeptide is ineffective in treating ankylosing spondylitis». Вместе они формируют уникальный семантический отпечаток (fingerprint).

Цитировать